Please provide your email address to receive an email when new articles are posted on . The most frequent cause of death in patients with rheumatoid arthritis-associated interstitial lung disease and ...

Chronic obstructive pulmonary disease (COPD) is a long-term lung disease affecting at least 15 million American adults. It’s also the fourth leading cause of disease-attributed death. This makes ...

Table 1 reports the total number of patients with COPD and the number experiencing an MI or stroke. There were 25,857 patients with COPD in 277 practices at the start of the observation period. Over ...

In addition to the new exacerbation data, the indication for Stiolto Respimat has been revised. The Food and Drug Administration (FDA) has approved updated labeling for Stiolto Respimat (tiotropium ...

The SPIROMICS study found considerable year-to-year heterogeneity in acute chronic obstructive pulmonary disease (COPD) exacerbation patterns over 3 years of follow-up. Similarly, a Danish nationwide ...

Analysis of insurance claims reveals that criteria other than the Healthcare Effectiveness Data and Information Set (HEDIS) persistent asthma definition can identify more at-risk patients with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Mepolizumab reduced the risk for a first severe ...

Pooled data from two identical 12-week pivotal Phase 3 trials (N=1229) in patients with moderate to very severe COPD showed that the mean annualized rate of all COPD exacerbations was 0.47, 0.45, and ...

To derive a clinical prediction rule (CPR) for short-term death following an acute exacerbation of COPD (AECOPD). All persons ⩾40 years (to exclude patients with potential asthma) attending a HC of ...

Only 15% of patients were adherent to ICS therapy 3 months after their asthma exacerbation, and less that one-fourth of those remained adherent 9 months later. Improved adherence to inhaled ...

Early initiation of maintenance medication in patients with moderate to severe COPD exacerbations is associated with reduced risk of future exacerbations and lower costs. Objectives: To examine the ...